{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:42:40Z","timestamp":1790678560989,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014584","name":"Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014584","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Despite the growing understanding of the carcinogenesis of pelvic high-grade serous carcinoma (HGSC) of the ovary and peritoneum and its precursor lesion serous tubal intraepithelial carcinoma (STIC), evidence-based proven recommendations on the clinical management of patients with STIC are lacking so far.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A questionnaire containing 21 questions was developed to explore the clinical experience with patients with the diagnosis of STICs and the diagnostic, surgical and histopathological approaches in Germany. Overall, 540 clinical heads of department in all German gynaecological centres were asked to participate.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>131 questionnaires (response rate 24.3%) were included in this survey. 45.8% of the respondents had treated one to three STIC patients during their career. 75.6% of the respondents performed opportunistic bilateral salpingectomies during other gynaecological surgeries. Most of the participants (31.3%) started with the SEE-FIM (Sectioning and Extensively Examining the FIMbria) protocol in 2014. It was requested by 39.7% centres for prophylactic salpingectomies, by 13.7% for both prophylactic and opportunistic salpingectomies and by 22.1% for neither of both. 38.2%, 1.5% and 24.4% of the participants would use the laparoscopic, transverse and midline laparotomic approach for a surgical staging procedure, respectively. 25.6% (54.7%) of the respondents recommended a hysterectomy in premenopausal (versus postmenopausal) patients with a STIC, 24.4% (88.4%) a bilateral oophorectomy and 50.0% (4.7%) an affected side oophorectomy (all <jats:italic>p<\/jats:italic> values\u2009&lt;\u20090.001). Omentectomy, pelvic and para-aortic lymphadenectomy would be performed by 60.5% (64.0%), 9.3% (11.6%) and 9.3% (11.6%) of respondents in premenopausal (versus postmenopausal) patients (all <jats:italic>p<\/jats:italic> values\u2009&gt;\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our survey highlights significant inconsistency in the management of patients with STIC. Prospective data are urgently needed to elucidate the clinical impact of a STIC lesion and its clinical management.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00404-023-06919-8","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T19:56:04Z","timestamp":1674849364000},"page":"527-534","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A questionnaire-based survey on the diagnostic and therapeutic approaches for patients with STIC in Germany"],"prefix":"10.1007","volume":"308","author":[{"given":"Josche","family":"van der Ven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8018-5484","authenticated-orcid":false,"given":"Valerie Catherine","family":"Linz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Anic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona Wanda","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelie","family":"Loewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slavomir","family":"Krajnak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kommoss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Schmalfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalid","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Hasenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Johannes","family":"Battista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,27]]},"reference":[{"issue":"1","key":"6919_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL et al (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7\u201333","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"6919_CR2","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/modpathol.2016.238","volume":"30","author":"EEK Meserve","year":"2017","unstructured":"Meserve EEK, Brouwer J, Crum CP (2017) Serous tubal intraepithelial neoplasia: the concept and its application. Mod Pathol 30(5):710\u2013721","journal-title":"Mod Pathol"},{"issue":"3","key":"6919_CR3","first-page":"848","volume":"7","author":"HX Li","year":"2014","unstructured":"Li HX et al (2014) Advances in serous tubal intraepithelial carcinoma: correlation with high grade serous carcinoma and ovarian carcinogenesis. Int J Clin Exp Pathol 7(3):848\u2013857","journal-title":"Int J Clin Exp Pathol"},{"issue":"3","key":"6919_CR4","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","volume":"34","author":"RJ Kurman","year":"2010","unstructured":"Kurman RJ, Shih I-M (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34(3):433\u2013443","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"6919_CR5","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/path.1000","volume":"195","author":"JM Piek","year":"2001","unstructured":"Piek JM et al (2001) Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 195(4):451\u2013456","journal-title":"J Pathol"},{"issue":"25","key":"6919_CR6","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1200\/JCO.2008.16.4814","volume":"26","author":"JW Carlson","year":"2008","unstructured":"Carlson JW et al (2008) Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol 26(25):4160\u20134165","journal-title":"J Clin Oncol"},{"issue":"23","key":"6919_CR7","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402\u20132416","journal-title":"JAMA"},{"key":"6919_CR8","first-page":"012464","volume":"8","author":"GU Eleje","year":"2018","unstructured":"Eleje GU et al (2018) Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations. Cochrane Database Syst Rev 8:012464","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"6919_CR9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/jnci\/djn442","volume":"101","author":"TR Rebbeck","year":"2009","unstructured":"Rebbeck TR, Kauff ND, Domchek SM (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101(2):80\u201387","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"6919_CR10","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1097\/IGC.0b013e3182a80ac8","volume":"23","author":"SL Wethington","year":"2013","unstructured":"Wethington SL et al (2013) Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC). Int J Gynecol Cancer 23(9):1603\u20131611","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"6919_CR11","doi-asserted-by":"publisher","first-page":"pky061","DOI":"10.1093\/jncics\/pky061","volume":"2","author":"G Samimi","year":"2018","unstructured":"Samimi G et al (2018) Population frequency of serous tubal intraepithelial carcinoma (STIC) in clinical practice using SEE-Fim protocol. JNCI Cancer Spectr 2(4):pky061","journal-title":"JNCI Cancer Spectr"},{"issue":"2","key":"6919_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.47343","volume":"5","author":"GE Hanley","year":"2022","unstructured":"Hanley GE et al (2022) Outcomes from opportunistic salpingectomy for ovarian cancer prevention. JAMA Netw Open 5(2):e2147343","journal-title":"JAMA Netw Open"},{"issue":"2","key":"6919_CR13","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/diagnostics10020102","volume":"10","author":"SE Bachert","year":"2020","unstructured":"Bachert SE et al (2020) Serous tubal intraepithelial carcinoma: a concise review for the practicing pathologist and clinician. Diagnostics (Basel) 10(2):102","journal-title":"Diagnostics (Basel)"},{"issue":"2","key":"6919_CR14","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/01.pas.0000180854.28831.77","volume":"30","author":"F Medeiros","year":"2006","unstructured":"Medeiros F et al (2006) The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 30(2):230\u2013236","journal-title":"Am J Surg Pathol"},{"key":"6919_CR15","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1200\/JCO.21.02016","volume":"40","author":"MP Steenbeek","year":"2022","unstructured":"Steenbeek MP et al (2022) Risk of peritoneal carcinomatosis after risk-reducing salpingo-oophorectomy: a systematic review and individual patient data meta-analysis. J Clin Oncol 40:1879\u20131891","journal-title":"J Clin Oncol"},{"issue":"5","key":"6919_CR16","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/cncr.31211","volume":"124","author":"MG Harmsen","year":"2018","unstructured":"Harmsen MG et al (2018) Peritoneal carcinomatosis after risk-reducing surgery in BRCA1\/2 mutation carriers. Cancer 124(5):952\u2013959","journal-title":"Cancer"},{"key":"6919_CR17","doi-asserted-by":"publisher","first-page":"951292","DOI":"10.3389\/fonc.2022.951292","volume":"12","author":"VC Linz","year":"2022","unstructured":"Linz VC, Loewe A, van der Ven J, Hasenburg A, Battista MJ (2022) Incidence of pelvic high-grade serous carcinoma after isolated STIC diagnosis: a systematic review of the literature. Front Oncol 12:951292","journal-title":"Front Oncol"},{"issue":"3","key":"6919_CR18","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/IGC.0000000000000639","volume":"26","author":"WY Chay","year":"2016","unstructured":"Chay WY et al (2016) Outcomes of incidental fallopian tube high-grade serous carcinoma and serous tubal intraepithelial carcinoma in women at low risk of hereditary breast and ovarian cancer. Int J Gynecol Cancer 26(3):431\u2013436","journal-title":"Int J Gynecol Cancer"},{"key":"6919_CR19","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, D.K., AWMF), S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren Langversion 4.0. AWMF-Registernummer: 032\/035OL, 03\/2020. Version 4.0."},{"key":"6919_CR20","unstructured":"Leiner DJ. SoSci Survey. 2019. Available at https:\/\/www.soscisurvey.de. p. [Computer software]"},{"key":"6919_CR21","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1136\/ijgc-2019-000308","volume":"29","author":"N Colombo","year":"2019","unstructured":"Colombo N et al (2019) ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Int J Gynecol Cancer 29:728","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"6919_CR22","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00428-021-03244-w","volume":"480","author":"JMA Bogaerts","year":"2022","unstructured":"Bogaerts JMA et al (2022) Recommendations for diagnosing STIC: a systematic review and meta-analysis. Virchows Arch 480(4):725\u2013737","journal-title":"Virchows Arch"},{"issue":"3","key":"6919_CR23","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ygyno.2015.09.018","volume":"139","author":"MG Patrono","year":"2015","unstructured":"Patrono MG et al (2015) Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): a comprehensive review. Gynecol Oncol 139(3):568\u2013572","journal-title":"Gynecol Oncol"},{"issue":"8","key":"6919_CR24","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.clon.2018.03.036","volume":"30","author":"NMA Van der Hoeven","year":"2018","unstructured":"Van der Hoeven NMA et al (2018) Outcome and prognostic impact of surgical staging in serous tubal intraepithelial carcinoma: a cohort study and systematic review. Clin Oncol (R Coll Radiol) 30(8):463\u2013471","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"8","key":"6919_CR25","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1097\/IGC.0000000000000791","volume":"26","author":"C Poon","year":"2016","unstructured":"Poon C et al (2016) Incidence and characteristics of unsuspected neoplasia discovered in high-risk women undergoing risk reductive bilateral salpingooophorectomy. Int J Gynecol Cancer 26(8):1415\u20131420","journal-title":"Int J Gynecol Cancer"},{"issue":"10290","key":"6919_CR26","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","volume":"397","author":"U Menon","year":"2021","unstructured":"Menon U et al (2021) Ovarian cancer population screening and mortality after long-term follow-up in the UK collaborative trial of ovarian cancer screening (UKCTOCS): a randomised controlled trial. Lancet 397(10290):2182\u20132193","journal-title":"Lancet"},{"issue":"22","key":"6919_CR27","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1001\/jama.2011.766","volume":"305","author":"SS Buys","year":"2011","unstructured":"Buys SS et al (2011) Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. JAMA 305(22):2295\u20132303","journal-title":"JAMA"},{"key":"6919_CR28","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1016\/j.ejso.2022.07.007","volume":"48","author":"C Marchetti","year":"2022","unstructured":"Marchetti C et al (2022) Risk reducing surgery with peritoneal staging in BRCA1\u20132 mutation carriers. A prospective study. Eur J Surg Oncol 48:2539","journal-title":"Eur J Surg Oncol"},{"key":"6919_CR29","first-page":"CD005344","volume":"4","author":"LR Medeiros","year":"2008","unstructured":"Medeiros LR et al (2008) Laparoscopy versus laparotomy for FIGO stage I ovarian cancer. Cochrane Database Syst Rev 4:CD005344","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"6919_CR30","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/j.ejca.2013.01.035","volume":"49","author":"A du Bois","year":"2013","unstructured":"du Bois A et al (2013) Borderline tumours of the ovary: a cohort study of the arbeitsgmeinschaft gynakologische onkologie (AGO) study group. Eur J Cancer 49(8):1905\u20131914","journal-title":"Eur J Cancer"},{"issue":"13","key":"6919_CR31","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1093\/jnci\/djq149","volume":"102","author":"B Trimbos","year":"2010","unstructured":"Trimbos B et al (2010) Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial. J Natl Cancer Inst 102(13):982\u2013987","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"6919_CR32","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/s41467-017-00962-1","volume":"8","author":"SI Labidi-Galy","year":"2017","unstructured":"Labidi-Galy SI et al (2017) High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun 8(1):1093","journal-title":"Nat Commun"},{"issue":"1","key":"6919_CR33","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1097\/SLA.0000000000004078","volume":"275","author":"VM Meyer","year":"2022","unstructured":"Meyer VM et al (2022) Global overview of response rates in patient and health care professional surveys in surgery: a systematic review. Ann Surg 275(1):e75\u2013e81","journal-title":"Ann Surg"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-023-06919-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-023-06919-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-023-06919-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T14:10:05Z","timestamp":1687788605000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-023-06919-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,27]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["6919"],"URL":"https:\/\/doi.org\/10.1007\/s00404-023-06919-8","relation":{},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,27]]},"assertion":[{"value":"7 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"V.C.L., J.V.D.V, A.L., M.W.S., B.S., J.S. and M.J.B. have no relevant financial or non-financial interests to disclose. M.S. reports personal fees from AstraZeneca, BioNTech, Daiichi Sankyo, Eisai, Lilly, MSD, Novartis, Pantarhei Bioscience, Pfizer, Roche, and SeaGen outside the submitted work; institutional research funding from AstraZeneca, BioNTech, Eisai, Genentech, German Breast Group, Novartis, Palleos, Pantarhei Bioscience, Pierre Fabre, and SeaGen. In addition, M.S. has a patent for EP 2390370 B1 issued and a patent for EP 2951317 B1 issued. K.A. reports personal fees from Eisai, Roche Pharma AG, MSD, AstraZeneca and Clovis Oncology. Sl.K. received speaker honoraria from Roche and Novartis, research funding from Novartis and travel reimbursement from PharmaMar and Novartis. St.K. received honoraria for advisory boards and\/or educational activities (outside submitted work) from Roche, Astra Zeneca, GSK, Myriad, Clovis, MSD. A.H. reports honoraria and expenses from AstraZeneca, FBA Frauen\u00e4rzte BundesAkademie GmbH, KlarigoVerlag, MedConcept, Med public GmbH, Med update GmbH, Medicultus, Pfizer, Promedicis GmbH, Pierre Fabre Pharma GmbH, Softconsult, Roche Pharma AG, Streamedup! GmbH, Tesaro Bio Germany GmbH. A.H. is consultant to PharmaMar, Promedicis GmbH, Pierre Fabre Pharma GmbH, Roche Pharma AG and Tesaro Bio Germany GmbH and has received funded research from Celgene. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is a questionnaire-based survey and no ethical approval is required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}}]}}